Susan L Uprichard

List of Publications by Year
in descending order

37	3,451	430874 18	330143 37
papers	citations	h-index	g-index

39	39	39	3712
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naÃ¯ve and Experienced Individuals. Viruses, 2022, 14, 370.	3.3	5
2	Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. Journal of Virology, 2021, 95, e0049220.	3.4	14
3	HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics. Viruses, 2021, 13, 1308.	3.3	9
4	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. Viruses, 2021, 13, 1743.	3.3	15
5	Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. ELife, 2021, 10, .	6.0	4
6	Modeling based response guided therapy in subjects with recent hepatitis C infection. Antiviral Research, 2020, 180, 104862.	4.1	6
7	Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration. Journal of Infectious Diseases, 2020, 222, 1165-1169.	4.0	10
8	Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Scientific Reports, 2020, 10, 17820.	3.3	20
9	Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Scientific Reports, 2020, 10, 7837.	3.3	24
10	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Research, 2019, 163, 149-155.	4.1	6
11	Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. Viruses, 2019, 11, 263.	3.3	1
12	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver International, 2019, 39, 826-834.	3.9	15
13	Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology, 2018, 68, 473-484.	7.3	30
14	Accounting for Spaceâ€"Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models. Viruses, 2018, 10, 200.	3.3	22
15	Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. Therapeutic Advances in Gastroenterology, 2017, 10, 68-73.	3.2	15
16	The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?. Scientific Reports, 2017, 7, 10233.	3.3	20
17	Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Research, 2017, 144, 281-285.	4.1	26
18	HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. PLoS ONE, 2017, 12, e0187409.	2.5	19

#	Article	IF	Citations
19	HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. Journal of Hepatology, 2016, 64, 1232-1239.	3.7	65
20	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infectious Diseases, The, 2015, 15, 1167-1174.	9.1	216
21	Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. Journal of Virology, 2015, 89, 6551-6561.	3.4	32
22	Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment. Gut, 2015, 64, 690-691.	12.1	5
23	Determining the Involvement and Therapeutic Implications of Host Cellular Factors in Hepatitis C Virus Cell-to-Cell Spread. Journal of Virology, 2014, 88, 5050-5061.	3.4	38
24	Establishment of mice with inheritable susceptibility to productive hepatitis C virus infection. Hepatology, 2014, 59, 2043-2046.	7.3	1
25	Unexpected Structural Features of the Hepatitis C Virus Envelope Protein 2 Ectodomain. Journal of Virology, 2014, 88, 10280-10288.	3.4	37
26	Hepatitis C virus Cell-to-cell Spread Assay. Bio-protocol, 2014, 4, .	0.4	7
27	Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10777-10782.	7.1	177
28	Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3991-3996.	7.1	298
29	The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology, 2010, 407, 110-119.	2.4	17
30	Cellâ€Based Hepatitis C Virus Infection Fluorescence Resonance Energy Transfer (FRET) Assay for Antiviral Compound Screening. Current Protocols in Microbiology, 2010, 18, Unit 17.5..	6.5	15
31	Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon. Journal of Virology, 2009, 83, 6383-6390.	3.4	56
32	Replication of a hepatitis C virus replicon clone in mouse cells. Virology Journal, 2006, 3, 89.	3.4	85
33	Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 773-778.	7.1	212
34	Robust hepatitis C virus infectionin vitro. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9294-9299.	7.1	1,597
35	The therapeutic potential of RNA interference. FEBS Letters, 2005, 579, 5996-6007.	2.8	142
36	Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1310-1315.	7.1	71

#	Article	IF	Citations
37	Cytokine-Sensitive Replication of Hepatitis B Virus in Immortalized Mouse Hepatocyte Cultures. Journal of Virology, 2002, 76, 5646-5653.	3.4	119